Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ALT-803 + Bintrafusp alfa + CV301 + NHS-IL12|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ALT-803||N-803|N803|N 803|nogapendekin alfa|ALT803|ALT 803||ALT-803 (nogapendekin alfa) is a fusion protein comprising a mutant version of IL-15 with increased activity and IL-15Ra fused to the Fc region of IgG1, which activates CD8+ T-cells and promotes effector activity, potentially resulting in increased antitumor immune response (PMID: 24404427, PMID: 31338557).|
|Bintrafusp alfa||MSB0011359C|M7824||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 107 TGFBR2 Antibody 2||Bintrafusp alfa is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798, PMID: 32461347).|
|CV301||CV-301|PANVAC|CV301-V/F|BN-CV301||CV301 is a poxvirus-based vaccine that encodes tumor antigens CEA and MUC-1, and 3 costimulatory molecules including B7.1, ICAM-1, and LFA-3, which may stimulate antitumor immune response (PMID: 31110074).|
|NHS-IL12||M9241|M-9241||NHS-IL12 (M9241) is an immunocytokine composed of IL-12 linked to human tumor necrosis factor targeted IgG1, which may result in enhanced anti-tumor immune response (PMID: 24681847).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04491955||Phase II||ALT-803 + Bintrafusp alfa + CV301 + NHS-IL12 ALT-803 + Bintrafusp alfa + CV301||Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers||Completed||USA||0|